Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656278 | 0.91 | SMN1; SMN2 (0.49) | SMN1; SMN2PARP2PARP1HSD11B1OPRM1 | |
| SCHEMBL4761029 | 0.84 | PARP2 (0.49) | SMN1; SMN2PARP2PARP1KMT2AKDM4E | |
| SCHEMBL4712761 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2PARP2PARP1KMT2ACHRM1 | |
| SCHEMBL4626252 | 0.79 | PARP2 (0.46) | PARP2PARP1KMT2AMEN1 | |
| SCHEMBL5375993 | 0.78 | CBX7 (0.33) | SMN1; SMN2PARP2KMT2AMEN1KDM4E | |
| SCHEMBL5368552 | 0.78 | PARP2 (0.41) | SMN1; SMN2PARP2HSD11B1OPRM1OPRL1 | |
| SCHEMBL20962673 | 0.78 | PARP2 (0.41) | SMN1; SMN2PARP2HSD11B1OPRM1OPRL1 | |
| SCHEMBL5376556 | 0.77 | PARP2 (0.44) | PARP2PARP1OPRM1OPRL1 | |
| SCHEMBL4627866 | 0.76 | OPRL1 (0.40) | OPRM1OPRL1KMT2AMEN1 | |
| SCHEMBL5376874 | 0.76 | MEN1 (0.33) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | claimed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | claimed |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | claimed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | TFPI, F12, F5 | SMN1; SMN2 2879/4885PARP2 3321/4885PARP1 1406/4885 |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, F12, F5 | SMN1; SMN2 2879/4885PARP2 3321/4885PARP1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.